RAFARM S.A
RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 that develops, produces, and distributes more than 100 generic and specialty pharmaceutical products across 7 therapeutic categories, exporting to over 60 countries and serving as contract manufacturer for 80 international pharma companies.
- Company typePrivate
- Founded1974
- HeadquartersAthens, Greece
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What RAFARM S.A does
RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 and headquartered in Neo Psychiko, Athens, with manufacturing and R&D operations in Paiania, Attica. The company develops, produces, and markets a diversified portfolio of more than 100 pharmaceutical products spanning 7 therapeutic categories—cardiovascular, neurological/urological, hormonal, oncology, respiratory, hematological, and ophthalmic—distributed in Greece through pharmacies and hospitals and exported to more than 60 countries across Europe, the United States, Canada, and globally. Exports represent over 30% of annual net revenue, and RAFARM serves as a contract manufacturing partner to 80 international pharmaceutical companies producing more than 100 products.
The company's technology stack centers on sterile and complex pharmaceutical manufacturing, including a 1,400 sqm sterile production area across five separate GMP-compliant production lines equipped with robotic filling for plastic vials and pre-filled syringes and ultra-modern sterile ophthalmic filling machinery, all under BMS-controlled environments. RAFARM holds 1,100 active pharmaceutical product licenses globally, was the first Greek pharmaceutical company to receive FDA certification for sterile and complex drug development and manufacturing, and currently markets 6 approved products in the United States with 7 more pending. The company invests 10% of annual net revenue into R&D, anchored by a 2,500 sqm ultra-modern R&D Center inaugurated in 2022. Innovation is increasingly routed through the BNS Ophthalmics (BNSO) joint venture with BioNanoSim—which applies the proprietary NTPO nanotechnology platform to novel ophthalmic drug delivery (with pipeline assets including a tacrolimus ophthalmic emulsion holding FDA orphan drug designation)—and through a partnership with Biovista applying AI-driven drug repurposing (COSS platform) in ophthalmology. A 120 million EUR capital program runs through 2027, of which 75 million EUR is allocated to R&D, alongside a Cleveland Clinic collaboration for corneal scar therapy announced in September 2025.
RAFARM S.A firmographics
Firmographics- Name
- RAFARM S.A
- Legal name
- ΡΑΦΑΡΜ ΑΝΩΝΥΜΟΣ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ
- Website
- https://rafarmgroup.gr
- Company type
- Private
- Founded year
- 1974
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 that develops, produces, and distributes more than 100 generic and specialty pharmaceutical products across 7 therapeutic categories, exporting to over 60 countries and serving as contract manufacturer for 80 international pharma companies.
- Ownership category
- akta.pro rank
RAFARM S.A industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Specialty Pharmaceutical Distributors (HLAIAJAB)
Keywords
Where RAFARM S.A is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Offices3 records
Markets served
RAFARM S.A business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales (Domestic): RAFARM sells its own-developed and manufactured pharmaceutical products through pharmacies and hospitals in Greece. The commercial team maintains a portfolio across 7 therapeutic categories and has launched 30 new products over the past five years.
- International Distribution/Co-marketing: RAFARM distributes pharmaceutical products manufactured by international partners in the Greek domestic market through co-marketing and distribution agreements.
- Contract Manufacturing: 80 pharmaceutical companies worldwide trust RAFARM for the production of more than 100 products. RAFARM develops and manufactures pharmaceutical products for international partners under manufacturing and supply agreements. Exports represent >30% of annual net revenue.
- Technology Transfer & Licensing: RAFARM conducts technology transfer projects, bringing products developed by other research teams into its production facilities. This includes pharmaceutical technology transfers covering solid, semi-solid, and liquid dosage forms.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
RAFARM S.A product offering
Product offeringCore offering
RAFARM S.A. is a Greek pharmaceutical company that develops, manufactures, and distributes branded generic and value-added pharmaceutical products across 7 therapeutic categories (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic). The company specializes in sterile and complex ophthalmic and injectable formulations, holds FDA certification for sterile manufacturing, and operates as a contract manufacturer for more than 80 international pharmaceutical companies. Products are sold through pharmacies and hospitals in Greece and exported to over 60 countries.
Product overview
RAFARM S.A. is a Greek pharmaceutical company and one of the largest in Greece with international presence, celebrating 50 years of operation since 1974. The company operates as a diversified pharmaceutical manufacturer with three main product categories: (1) Proprietary branded generic pharmaceuticals covering 7 therapeutic areas (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic) marketed under brand names like COMPRELAN, NYZOL, TIAQUEL, XIMLUCI, HUKYNDRA, and statin portfolios; (2) Joint venture subsidiary BNS Ophthalmics (BNSO) developing and producing innovative ophthalmic products using nanotechnology; and (3) Contract manufacturing services for 80+ pharmaceutical companies producing over 400 products. The company has FDA certification for sterile and complex injectable development and manufacturing, with focus on ophthalmic and injectable products including Value Added Medicines (VAM). Products are sold in Greece and exported to 60+ countries, with 6 products currently marketed in the US market.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Pharmaceuticals Portfolio Over 100 pharmaceutical products across 7 therapeutic categories including cardiovascular, nervous system, urological, hormonal, blood, respiratory, and ophthalmic medications. Over 1,100 active marketing authorizations worldwide. Sold in Greece and exported to 60+ countries.
- Sterile Injectables and Ophthalmic Formulations Sterile injectable pharmaceutical products including ophthalmic and injectable formulations produced in 1,400 sqm sterile areas across 5 separate production lines with robotic filling equipment for plastic vials, pre-filled syringes, and ultra-modern sterile ophthalmic filling machines.
- Value Added Medicines (VAM) Medicines that improve existing drugs through new dosage forms, new indications for active substances, and practical therapeutic regimens leading to better patient compliance, including complex generics and novel pharmaceutical combinations.
- BNS Ophthalmics (BNSO) Nanotechnology Ophthalmic Products Innovative ophthalmic pharmaceutical products developed using the NTPO nanotechnology platform, including BNSO-1 (Tacrolimus ophthalmic emulsion for chronic anterior uveitis), BNSO-2 (intravitreal steroid with prolonged release for macular edema and AMD), and BNSO-3 (topical dry eye treatment).
- Contract Manufacturing Services Contract manufacturing and development services for 80 international pharmaceutical companies, covering sterile ophthalmic and injectable products, co-development of new pharmaceutical products, supply for international markets, and technology transfer projects for solid, semi-solid, and liquid dosage forms.
- Distribution and Co-Marketing in Greek Market Distribution and co-marketing of pharmaceutical products manufactured by international partners in the Greek domestic market, leveraging RAFARM's commercial reach and regulatory expertise.
Quantifiable outcome
- 100+ pharmaceutical products developed
- +5 more outcomes
Companies that use RAFARM S.A
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
RAFARM S.A technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
RAFARM S.A partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Cleveland CliniccoreStrategic collaboration between RAFARM and Cleveland Clinic for the development of an innovative, non-invasive ophthalmological therapy based on drug repurposing, targeting corneal scar healing - an unmet medical need. RAFARM handles all development process: preclinical trials, clinical studies, formulation optimization, industrial-scale production, and global commercial exploitation.
- Joseph PapaminorJoseph Papa, former Chairman and CEO of Bausch & Lomb, appointed to the Board of Directors of BNS Ophthalmics (BNSO). Brings over 30 years of leadership experience in global pharmaceutical companies for branded and generic drugs across therapeutic areas.
- Ari KellenminorAri Kellen, experienced healthcare and pharmaceutical executive, appointed to the Board of Directors of BNS Ophthalmics (BNSO). Former Senior Partner at McKinsey & Company, previously led multi-billion dollar P&L at Bausch & Lomb.
- BioNanoSim (BNS)coreJoint venture BNS Ophthalmics (BNSO) established between BNS and RAFARM to develop, produce, and commercialize innovative ophthalmic pharmaceutical products using BNS's proprietary NTPO nanotechnology platform for ophthalmic drug delivery. BNS contributes IP and R&D expertise; RAFARM provides funding and manufacturing infrastructure for commercial-scale production.
- University of Athens, Thessaloniki, Patras, Crete, IoanninaminorRAFARM has developed significant collaborations with renowned academic institutions in Greece for research and development activities.
- National Centre for Scientific Research 'Democritus'minorCollaboration with 'Democritus' research institute for scientific research activities.
- National Hellenic Research Foundation (NHRF)minorCollaboration with NHRF for research and development activities.
- University of Michigan, USAminorInternational research collaboration with University of Michigan for pharmaceutical R&D activities.
- University of Pisa, ItalyminorInternational research collaboration with University of Pisa, Italy, for pharmaceutical R&D activities.
- PadagisminorRAFARM co-developed an ophthalmic product with Padagis, which received FDA approval in 2022 for the US market.
- 80 International Pharmaceutical Companiesminor80 pharmaceutical companies worldwide trust RAFARM for the production of more than 100 pharmaceutical products. RAFARM serves as their manufacturing partner.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
RAFARM S.A competitors and assessment
Company assessmentDirect peers
- KRKA: KRKA is a Slovenian-based generic pharmaceutical manufacturer with broad therapeutic area coverage, strong international exports to 70+ countries, and contract manufacturing capabilities. Highly comparable to RAFARM as a Central/Eastern European mid-sized generic pharma with similar export orientation and contract manufacturing model.
- Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharmaceutical company with branded generics, specialty pharmaceuticals (particularly in women's health and CNS), and significant export operations across Europe and CIS. Comparable to RAFARM as an Eastern European pharma player with diversified therapeutic portfolio and international manufacturing footprint.
- Stada Arzneimittel: Stada is a German-headquartered European generics and specialty pharma company with broad therapeutic coverage and significant presence across European markets. Directly comparable to RAFARM in branded generic strategy, European geographic focus, and contract manufacturing services.
- Polpharma: Polpharma is one of the largest Polish pharmaceutical manufacturers, producing generic drugs and APIs with operations across Central/Eastern Europe. Comparable to RAFARM in size, branded generic focus, and EU export orientation from a regional manufacturing base.
- Pharmathen: Pharmathen is a Greek-headquartered specialty pharmaceutical company focused on generics, complex injectables, and ophthalmic products with strong European export presence. Most direct geographic peer to RAFARM, with overlapping therapeutic areas and similar contract manufacturing/drug development capabilities.
- ELPEN Pharmaceutical: ELPEN is another major Greek pharmaceutical manufacturer producing branded generics across cardiovascular, respiratory, and other therapeutic areas with international presence. Direct domestic peer to RAFARM with similar branded generic strategy and therapeutic portfolio focus.
- Padagis: Padagis is a US-based specialty pharmaceutical company focused on extended topical, ophthalmic, and dermatological products. RAFARM has co-developed an FDA-approved ophthalmic product with Padagis (2022 approval), making it both a direct partner and direct peer in ophthalmology specialty generics.
Broad incumbents
- Viatris: Viatris is a global pharmaceutical major formed from the Mylan-Upjohn merger, offering a broad portfolio of branded and generic medicines across therapeutic areas including ophthalmology. Comparable as a generic/specialty pharma incumbent with overlapping therapeutic categories, though at substantially larger scale than RAFARM.
- Bausch + Lomb: Bausch + Lomb is a global ophthalmology-focused pharmaceutical and medical device company, with leadership in ocular pharmaceuticals including branded ophthalmics. Highly relevant for benchmarking RAFARM's ophthalmology strategy and BNSO pipeline ambition, and notably shares board member overlap via Joseph Papa.
- Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive specialty pharma operations including branded ophthalmology products. Comparable as a broad incumbent in the same generics and ophthalmology spaces RAFARM serves, though at vastly larger scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
RAFARM S.A social profiles
Digital presenceRAFARM S.A compliance and trust
Trust signalCompliance2 records
RAFARM S.A financial estimates
Financial estimateRevenue estimate
Valuation estimate
RAFARM S.A leadership team
Management profileNumber of profiles
Profiles10 records
RAFARM S.A subsidiaries and ownership
Company hierarchySubsidiaries1 record
RAFARM S.A funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RAFARM S.A M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RAFARM S.A
What does RAFARM S.A do?
RAFARM S.A. is a Greek pharmaceutical company that develops, manufactures, and distributes branded generic and value-added pharmaceutical products across 7 therapeutic categories (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic). The company specializes in sterile and complex ophthalmic and injectable formulations, holds FDA certification for sterile manufacturing, and operates as a contract manufacturer for more than 80 international pharmaceutical companies. Products are sold through pharmacies and hospitals in Greece and exported to over 60 countries.
Is RAFARM S.A a public or private company?
RAFARM S.A is a private company. It is classified as family owned and is currently operating.
When was RAFARM S.A founded?
RAFARM S.A was founded in 1974. It employs 501 to 1,000 people.
Where is RAFARM S.A based?
RAFARM S.A is headquartered in Athens, Greece, in the Europe region.
How does RAFARM S.A make money?
Four revenue lines are on record. Pharmaceutical Product Sales (Domestic) is the primary driver. The others are international Distribution/Co-marketing, contract Manufacturing and technology Transfer & Licensing.
Who are RAFARM S.A's main competitors?
Direct peers on record are KRKA, Gedeon Richter, Stada Arzneimittel, Polpharma, Pharmathen, ELPEN Pharmaceutical and Padagis. Broad incumbents are Viatris, Bausch + Lomb and Teva Pharmaceutical Industries.
Does RAFARM S.A have an API?
No public API is recorded for RAFARM S.A.
What industry is RAFARM S.A in?
RAFARM S.A's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.